ARVN Arvinas, Inc.
$7.43
Arvinas, Inc. (ARVN) Earnings News
Earnings press releases, previews and reviews for Arvinas, Inc. (ARVN), newest first.
Thursday
October 1, 2026
4:01 PM ET
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Monday
September 28, 2026
7:00 AM ET
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Tuesday
August 4, 2026
7:00 AM ET
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tuesday
July 28, 2026
7:00 AM ET
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Thursday
June 4, 2026
8:00 AM ET
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Tuesday
May 12, 2026
7:05 AM ET
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Tuesday
May 5, 2026
7:00 AM ET
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026